| Literature DB >> 32646434 |
Haifeng Xu1,2, Jianfei Pang1, Xi Yang2, Mei Li3, Dongsheng Zhao4.
Abstract
BACKGROUND: Although clinical guidelines provide the best practice for medical activities, there are some limitations in using clinical guidelines to assistant decision-making in practical application, such as long update cycle and low compliance of doctors with the guidelines. Driven by data of actual cases, process mining technology provides the possibility to remedy these shortcomings of clinical guidelines.Entities:
Keywords: Clinical decision support; Clinical guideline; Predictive process monitoring; Stroke thrombolytic therapy
Mesh:
Substances:
Year: 2020 PMID: 32646434 PMCID: PMC7346378 DOI: 10.1186/s12911-020-1111-6
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Indications and Contraindications for rt-PA intravenous thrombolysis within 3 h
| Type | No. | Eligibility Recommendations |
|---|---|---|
| Indications | 1 | Symptoms of neurological impairment caused by ischemic stroke |
| 2 | Within 3 h of ischemic stroke symptom from onset or patient last known well or at baseline state. | |
| 3 | Patients older than 18 years | |
| 4 | Informed consent signed by patient or family member | |
| Contraindications | 1 | Intracranial hemorrhage |
| 2 | With history of intracranial hemorrhage | |
| 3 | Stroke or severe head injury within 3 months | |
| 4 | Intracranial neoplasms or giant intracranial aneurysms | |
| 5 | Intracranial or intraspinal surgery within 3 months | |
| 6 | Received large surgery within 2 weeks | |
| 7 | Gastrointestinal bleed or urinary system hemorrhage within 3 weeks | |
| 8 | Associated with active visceral hemorrhage | |
| 9 | Associated with aortic arch dissection | |
| 10 | Arterial punctures with difficult to hemostasis in the past week | |
| 11 | Blood pressure > 180/100 mmHg | |
| 12 | Platelet count < 100* 109/L | |
| 13 | Treatment with low-molecular-weight heparin within 24 h | |
| 14 | international normalized ratio (INR) > 1.7 or Prothrombin time (PT) > 15 s | |
| 15 | Treatment with thrombin inhibitors or factor Xa inhibitors within 48 h, or abnormal laboratory examinations | |
| 16 | Blood glucose < 2.8 mmol/L or blood glucose > 22.22 mmol/L | |
| 17 | Large area of head infarction |
Data attributes in the event log
| Type | Example | |
|---|---|---|
| Case (static) | Categorical | Patient’s gender |
| Numeric | Patient’s age | |
| Textual | Description of the application | |
| Event (dynamic) | Categorical | Activity, resource |
| Numeric | Amount paid | |
| Textual | Patient’s medical history |
Fig. 1Three operational support activities: detect, predict, and recommend
Fig. 2Framework of predictive process monitoring
Fig. 3Original data features and predictive variables
Therapeutic method in the data set
| Intravenous thrombolysis | Endovascular treatment | Others | |||
|---|---|---|---|---|---|
| rt-PA | urokinase | Mechanical | Arterial thrombolysis | ||
| rt-PA | urokinase | ||||
| 123 | 5 | 15 | 86 | 59 | 903 |
A fragment of data set
| ID | Practical thrombolysis | Comply with the guidelines | Age | OTC | Glucose | Platelet count | Blood pressure | FAST | MRA | Coag | Statin | … |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 0 | 75 | 3 | 7.9 | 550 | 150/80 | 2 | 0 | 1 | 1 | |
| 2 | 0 | 1 | 88 | 5 | 11.52 | 200 | 120/70 | 1 | 1 | 1 | 0 | |
| 3 | 0 | 0 | 80 | 12 | 16.69 | 110 | 140/90 | 1 | 0 | 1 | 0 | |
| 4 | 1 | 1 | 56 | 8 | 6.48 | 430 | 130/76 | 2 | 0 | 0 | 1 | |
| 5 | 0 | 1 | 70 | 7 | 5.34 | 230 | 200/90 | 1 | 1 | 1 | 0 | |
| … |
Fig. 4Checking results of the data set
Experimental results on test set
| Clinical application | Prediction model | ACC | Precision | Recall | F1 | AUC | |||
|---|---|---|---|---|---|---|---|---|---|
| throm | Non-throm | throm | Non-throm | throm | Non-throm | ||||
| Intravenous thrombolysis | DT without control flow | 0.87 | 0.49 | 0.96 | 0.77 | 0.89 | 0.60 | 0.92 | 0.83 |
| DT with control flow | 0.93 | 0.64 | 0.99 | 0.96 | 0.92 | 0.77 | 0.96 | 0.94 | |
| RF without control flow | 0.88 | 0.51 | 0.99 | 0.93 | 0.87 | 0.65 | 0.93 | 0.90 | |
| RF with control flow | 0.96 | 0.82 | 0.98 | 0.88 | 0.97 | 0.85 | 0.98 | 0.93 | |
| Clinical guidelines | 0.91 | 0.64 | 0.95 | 0.68 | 0.95 | 0.66 | 0.95 | 0.81 | |
| Arterial thrombolysis | DT without control flow | 0.74 | 0.29 | 0.93 | 0.62 | 0.76 | 0.39 | 0.83 | 0.69 |
| DT with control flow | 0.85 | 0.48 | 0.97 | 0.82 | 0.86 | 0.60 | 0.91 | 0.84 | |
| RF without control flow | 0.82 | 0.39 | 0.92 | 0.54 | 0.86 | 0.45 | 0.89 | 0.70 | |
| RF with control flow | 0.91 | 0.65 | 0.96 | 0.76 | 0.93 | 0.70 | 0.95 | 0.85 | |
| Clinical guidelines | 0.89 | 0.73 | 0.91 | 0.36 | 0.98 | 0.48 | 0.94 | 0.67 | |
Proportions of each medical activity
| Anti-platelet | Statin | MRA | Coagulation | |||||
|---|---|---|---|---|---|---|---|---|
| throm | Non-throm | throm | Non-throm | throm | Non-Throm | throm | Non-throm | |
| Intravenous thrombolysis | 8/128 | 396/918 | 10/128 | 177/918 | 7/128 | 204/918 | 44/128 | 746/918 |
| Arterial thrombolysis | 17/145 | 712/918 | 16/145 | 500/918 | 19/145 | 287/918 | 78/145 | 849/918 |